miRNA在急性冠脉综合征中的临床研究进展

Clinical research progresses of mi RNAs in acute coronary syndrome

急性冠脉综合征(ACS)的发生率和病死率日趋增高,基因治疗已成为当今临床研究领域的热点,而miRNA是很有临床转化应用前景的一类新型目的基因。在ACS中,心肌特异性的miRNA的表达会有所改变,如miR-1、miR-133、miR-208、miR-499在组织和血液中均有显著变化,因此它们有望成为理想的新型生物学标志物,用于ACS的早期诊断及判断预后。尤其是miR-499和miR-208,几乎仅在心肌中表达,具有高度特异性,应用前景广阔。同时,miRNA也可作为心血管疾病新药物作用靶点以达到治疗的效果;通过过表达或拮抗相关miRNA的表达水平,可缓解病程进展,消除部分症状。该文就miRNA在ACS的临床研究进展进行综述。

The morbidity and mortality of acute coronary syndrome （ACS） are gradually increasing. Gene therapy has become a hot spot in clinical research and microRNAs （miRNAs） are novel target genes with a promising future in clinical application. For ACS, the expressions of cardiac-specific miRNAs will change in both tissues and blood such as miR-1, miR-133, miR-208, and miR-499, which may be ideal new biomarkers for early diagnosis and predicting the prognosis of ACS. miR-499 and miR-208 are particularly prospective because they only express in myocardium with high specificity. Meanwhile, miRNAs may also serve as targets of new cardiovascular drugs, which can slow down the disease progression and alleviate some symptoms via over-expressions or suppression of expressions of related miRNAs. This article reviews clinical research progresses of microRNAs in ACS.